Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is PDL BioPharma Inc. (PDLI) Going to Burn These Hedge Funds?

Page 1 of 2

We, at Insider Monkey, have gone over 700 13F filings that hedge funds and prominent investors are required to file by the government. The 13F filings show the funds’ and investors’ portfolio positions as of September 30. In this article, we look at what those funds think of PDL BioPharma Inc. (NASDAQ:PDLI) based on that data.

PDL BioPharma Inc. (NASDAQ:PDLI) shareholders have witnessed an increase in hedge fund sentiment recently. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity, but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Wilshire Bancorp Inc (NASDAQ:WIBC), National CineMedia, Inc. (NASDAQ:NCMI), and Acceleron Pharma Inc (NASDAQ:XLRN) to gather more data points.

Follow Pdl Biopharma Inc. (NASDAQ:PDLI)
Trade (NASDAQ:PDLI) Now!

According to most stock holders, hedge funds are viewed as worthless, outdated investment tools of yesteryear. While there are over 8000 funds trading at the moment, Our experts choose to focus on the moguls of this club, about 700 funds. These money managers shepherd the lion’s share of the smart money’s total capital, and by paying attention to their best investments, Insider Monkey has spotted many investment strategies that have historically outrun the market. Insider Monkey’s small-cap hedge fund strategy outstripped the S&P 500 index by 12 percentage points a year for a decade in their back tests.

Now, we’re going to take a look at the recent action encompassing PDL BioPharma Inc. (NASDAQ:PDLI).

Hedge fund activity in PDL BioPharma Inc. (NASDAQ:PDLI)

At the end of the third quarter, a total of 20 of the hedge funds tracked by Insider Monkey were long this stock, an increase of 43% from the second quarter. With the smart money’s positions undergoing their usual ebb and flow, there exists a few key hedge fund managers who were increasing their holdings significantly (or already accumulated large positions).

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Renaissance Technologies has the biggest position in PDL BioPharma Inc. (NASDAQ:PDLI), worth close to $45.3 million, amounting to 0.1% of its total 13F portfolio. Coming in second is Joel Greenblatt of Gotham Asset Management, with a $25.4 million position; the fund has 0.2% of its 13F portfolio invested in the stock. Some other members of the smart money that hold long positions consist of John Overdeck and David Siegel’s Two Sigma Advisors, Israel Englander’s Millennium Management and Cliff Asness’ AQR Capital Management.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!